Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Sponsor: Beam Therapeutics Inc.
Summary
This is a Phase 1/2, multicenter, open-label, single-ascending-dose study to evaluate the safety, tolerability, and efficacy of BEAM-301 in adult patients with GSDIa homozygous or compound heterozygous for the G6PC1 c.247C\>T (p.R83C) variant and to determine the optimal biological dose.
Official title: A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) Homozygous or Compound Heterozygous for the G6PC1 c.247C>T (p.R83C) Variant
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2024-12-06
Completion Date
2027-12-30
Last Updated
2025-12-15
Healthy Volunteers
No
Conditions
Interventions
BEAM-301: Single dose of BEAM-301 administered by IV
BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
Locations (3)
Clinical Study Site
Orange, California, United States
Clinical Study Site
Farmington, Connecticut, United States
Clinical Study Site
Houston, Texas, United States